摘要: For more than 50 years, a major goal of research in cancer therapeutics has been to develop universally effective agents that render cells sensitive cytotoxic chemotherapy without substantially increasing toxicity normal cells. The results recent clinical trials indicate certain antiangiogenic drugs may produce this long-sought effect. Here, I describe three distinct mechanisms help explain the chemosensitizing activity these drugs: normalizing tumor vasculature, preventing rapid cell repopulation, and augmenting antivascular effects chemotherapy. then discuss how potential might be exploited maximize therapeutic efficacy.
sciencemag.org
harvard.edu参考文章(45)
Judah Folkman, Birgit M. Kräling, Catherine E. Butterfield, Blair Marshall, Timothy Browder, Michael S. O’Reilly, Bin Shi, Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer Cancer Research. ,vol. 60, pp. 1878- 1886 ,(2000)
Gillian M. Tozer, Chryso Kanthou, Bruce C. Baguley, Disrupting tumour blood vessels Nature Reviews Cancer. ,vol. 5, pp. 423- 435 ,(2005) , 10.1038/NRC1628
David E. Cohn, Sue Valmadre, Kimberly E. Resnick, Lynne A. Eaton, Larry J. Copeland, Jeffrey M. Fowler, Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecologic Oncology. ,vol. 102, pp. 134- 139 ,(2006) , 10.1016/J.YGYNO.2006.01.030
John J. Kim, Ian F. Tannock, Repopulation of cancer cells during therapy: an important cause of treatment failure Nature Reviews Cancer. ,vol. 5, pp. 516- 525 ,(2005) , 10.1038/NRC1650
Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers, Douglas Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell. ,vol. 8, pp. 299- 309 ,(2005) , 10.1016/J.CCR.2005.09.005
J. Marx, CANCER: Encouraging Results for Second-Generation Antiangiogenesis Drugs Science. ,vol. 308, pp. 1248- 1249 ,(2005) , 10.1126/SCIENCE.308.5726.1248
Louis M. Sherwood, Edith E. Parris, Judah Folkman, Tumor Angiogenesis: Therapeutic Implications New England Journal of Medicine. ,vol. 285, pp. 1182- 1186 ,(1971) , 10.1056/NEJM197111182852108
Mark W Kieran, Christopher D Turner, Joshua B Rubin, Susan N Chi, Mary Ann Zimmerman, Christine Chordas, Giannoula Klement, Andrea Laforme, Amanda Gordon, Amanda Thomas, Donna Neuberg, Timothy Browder, Judah Folkman, A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. Journal of Pediatric Hematology Oncology. ,vol. 27, pp. 573- 581 ,(2005) , 10.1097/01.MPH.0000183863.10792.D4
Tamar Alon, Itzhak Hemo, Ahuva Itin, Jacob Pe'er, Jonathan Stone, Eli Keshet, Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Medicine. ,vol. 1, pp. 1024- 1028 ,(1995) , 10.1038/NM1095-1024
Rakesh K Jain, Dan G Duda, Jeffrey W Clark, Jay S Loeffler, Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nature Reviews Clinical Oncology. ,vol. 3, pp. 24- 40 ,(2006) , 10.1038/NCPONC0403